These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28689531)

  • 1. Comparison of Lipoprotein Electrophoresis and Apolipoprotein E Genotyping in Investigating Dysbetalipoproteinemia.
    Ahmed F; El-Kadiki A; Gibbons S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):378-379. PubMed ID: 28689531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Chappell DA
    J Clin Invest; 1989 Dec; 84(6):1906-15. PubMed ID: 2556448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
    Lin HP; Kao JT
    Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
    Murase T; Okubo M; Takeuchi I
    J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3.
    Havel RJ; Kotite L; Kane JP; Tun P; Bersot T
    J Clin Invest; 1983 Jul; 72(1):379-87. PubMed ID: 6860421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
    Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
    Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
    Mann WA; Gregg RE; Sprecher DL; Brewer HB
    Biochim Biophys Acta; 1989 Oct; 1005(3):239-44. PubMed ID: 2804053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy.
    Oikawa S; Suzuki N; Sakuma E; Saito T; Namai K; Kotake H; Fujii Y; Toyota T
    Am J Kidney Dis; 1991 Nov; 18(5):553-8. PubMed ID: 1951334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
    Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.
    Utermann G; Vogelberg KH; Steinmetz A; Schoenborn W; Pruin N; Jaeschke M; Hees M; Canzler H
    Clin Genet; 1979 Jan; 15(1):37-62. PubMed ID: 215360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Deshaies Y; Gagné C; Couture P
    Atherosclerosis; 2006 Sep; 188(1):203-12. PubMed ID: 16337207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.
    Marais D
    Curr Opin Lipidol; 2015 Aug; 26(4):292-7. PubMed ID: 26103610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.
    Blom DJ; Byrnes P; Jones S; Marais AD
    J Lipid Res; 2003 Jan; 44(1):212-7. PubMed ID: 12518040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency.
    Paquette M; Bernard S; Paré G; Baass A
    J Clin Endocrinol Metab; 2022 Jan; 107(2):538-548. PubMed ID: 34467996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
    Smelt AH; de Beer F
    Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of a new variant of apolipoprotein E (apo E-Kochi).
    Suehiro T; Yoshida K; Yamano T; Ohno F
    Jpn J Med; 1990; 29(6):587-94. PubMed ID: 2101409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.
    Stalenhoef AF; Malloy MJ; Kane JP; Havel RJ
    J Clin Invest; 1986 Sep; 78(3):722-8. PubMed ID: 3745433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
    de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
    Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III].
    Hagve TA; Furuset T; Christophersen B; Ose L
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):853-6. PubMed ID: 8480294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ; Frants RR; Havekes LM
    J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.